NO991225D0 - Terapi for <alfa>-galaktosidase A mangel - Google Patents

Terapi for <alfa>-galaktosidase A mangel

Info

Publication number
NO991225D0
NO991225D0 NO991225A NO991225A NO991225D0 NO 991225 D0 NO991225 D0 NO 991225D0 NO 991225 A NO991225 A NO 991225A NO 991225 A NO991225 A NO 991225A NO 991225 D0 NO991225 D0 NO 991225D0
Authority
NO
Norway
Prior art keywords
galactosidase
alfa
therapy
deficiency
sample
Prior art date
Application number
NO991225A
Other languages
English (en)
Other versions
NO991225L (no
NO328443B1 (no
Inventor
Richard F Selden
Marianne Borowski
Francis P Gillespie
Carol M Kinoshita
Douglas A Treco
Melanie D Williams
Original Assignee
Transkaryotic Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transkaryotic Therapies Inc filed Critical Transkaryotic Therapies Inc
Publication of NO991225D0 publication Critical patent/NO991225D0/no
Publication of NO991225L publication Critical patent/NO991225L/no
Publication of NO328443B1 publication Critical patent/NO328443B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
NO19991225A 1996-09-13 1999-03-12 DNA-molekyl, ekspresjonskonstruksjon, dyrket human celle, kloncellestamme, kloncellelinje, protein, fremgangsmate for fremstilling av glykosylert human alfa-galaktosidase A og human alfa-galaktosidase A samt anvendelse av en human celle som er genetisk modifisert. NO328443B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71261496A 1996-09-13 1996-09-13
PCT/US1997/016603 WO1998011206A2 (en) 1996-09-13 1997-09-12 THERAPY FOR α-GALACTOSIDASE A DEFICIENCY

Publications (3)

Publication Number Publication Date
NO991225D0 true NO991225D0 (no) 1999-03-12
NO991225L NO991225L (no) 1999-05-10
NO328443B1 NO328443B1 (no) 2010-02-22

Family

ID=24862863

Family Applications (4)

Application Number Title Priority Date Filing Date
NO19991225A NO328443B1 (no) 1996-09-13 1999-03-12 DNA-molekyl, ekspresjonskonstruksjon, dyrket human celle, kloncellestamme, kloncellelinje, protein, fremgangsmate for fremstilling av glykosylert human alfa-galaktosidase A og human alfa-galaktosidase A samt anvendelse av en human celle som er genetisk modifisert.
NO20090583A NO330687B1 (no) 1996-09-13 2009-02-06 Fremgangsmate for rensing av human alfa-galaktosidase A
NO20110496A NO340408B1 (no) 1996-09-13 2011-03-31 Fremgangsmåte for å produsere humant alfa-galaktosidase A, og farmasøytisk preparat
NO20141168A NO20141168L (no) 1996-09-13 2014-09-29 Fremgangsmåte for rensing av human alfa-galaktosidase A fra en prøve

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO20090583A NO330687B1 (no) 1996-09-13 2009-02-06 Fremgangsmate for rensing av human alfa-galaktosidase A
NO20110496A NO340408B1 (no) 1996-09-13 2011-03-31 Fremgangsmåte for å produsere humant alfa-galaktosidase A, og farmasøytisk preparat
NO20141168A NO20141168L (no) 1996-09-13 2014-09-29 Fremgangsmåte for rensing av human alfa-galaktosidase A fra en prøve

Country Status (21)

Country Link
EP (4) EP2327775A3 (no)
JP (7) JP4001925B2 (no)
KR (2) KR20050084473A (no)
CN (1) CN1268741C (no)
AT (1) ATE286120T1 (no)
AU (1) AU4424497A (no)
CA (1) CA2265464C (no)
DE (1) DE69732129T2 (no)
DK (2) DK1538202T3 (no)
ES (3) ES2581828T3 (no)
HK (3) HK1022173A1 (no)
HU (2) HU230275B1 (no)
IL (2) IL128960A (no)
MX (1) MX340738B (no)
NO (4) NO328443B1 (no)
NZ (2) NZ506214A (no)
PL (1) PL190041B1 (no)
PT (1) PT1538202E (no)
RU (1) RU2179034C2 (no)
TW (1) TW585919B (no)
WO (1) WO1998011206A2 (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
EP1658857A1 (en) * 1997-10-29 2006-05-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
EP2147681A1 (en) * 1997-10-29 2010-01-27 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU2016250357B2 (en) * 1999-03-11 2018-11-01 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
AU2004242550B2 (en) * 1999-03-11 2008-04-03 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
AU2012241170B2 (en) * 1999-03-11 2016-07-28 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
EP2275559A3 (en) * 1999-09-28 2011-03-23 Shire Human Genetic Therapies, Inc. Optimized messenger RNA
WO2002064799A2 (en) 1999-09-28 2002-08-22 Transkaryotic Therapies, Inc. Optimized messenger rna
AU1647501A (en) 1999-12-10 2001-06-18 Cytos Biotechnology Ag Replicon based activation of endogenous genes
BR0108077A (pt) 2000-02-04 2002-10-22 Children S Hospital Res Founda Processo para reduzir placas ateroscleróticas em um mamìfero, método para tratamento da aterosclerose em um mamìfero, composição, métodos para prover proteìna ou polipeptìdeo hidrolisante de lipìdeo biologicamente ativo ou mistura deles, para células de um mamìfero tendo deficiência na proteìna ou polipeptìdeo hidrolisante de lipìdeo biologicamente ativo , para prover lipase de ácido lisossomal biologicamente ativa para células de um mamìfero tendo deficiência de lipase de ácido lisossomal biologicamente ativa, para prover lipase de ácido lisossoal biologicamente ativa para células de um mamìfero com aterosclerose, para tratamento da doença de wolman em um mamìfero, para tratamento de doença de armazenagem de colesteril éster em um mamìfero, e, para tratamento da aterosclerose em um mamìfero
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
IL140110A0 (en) * 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
AU2003228722B2 (en) 2002-04-25 2009-06-25 Takeda Pharmaceutical Company Limited Treatment of alpha-galactosidase A deficiency
JP5433133B2 (ja) * 2003-01-22 2014-03-05 デューク・ユニヴァーシティ リソソームポリペプチドを発現するための改善された構築物
WO2007058381A1 (ja) 2005-11-18 2007-05-24 Tokyo Metropolitan Organization For Medical Research 基質特異性を変換した新規高機能酵素
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
PT1986612E (pt) 2006-02-07 2012-11-06 Shire Human Genetic Therapies Composição estável de glucocerebrosidase
EP3459441A1 (en) 2006-02-09 2019-03-27 Genzyme Corporation Slow intraventricular delivery
JP5507242B2 (ja) * 2007-05-18 2014-05-28 公益財団法人東京都医学総合研究所 酵素補充療法用医薬組成物
CN105879047A (zh) 2008-12-16 2016-08-24 建新公司 寡糖-蛋白缀合物
AU2010281403B2 (en) 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
SI2561069T1 (sl) 2010-04-23 2017-07-31 Alexion Pharmaceuticals, Inc. Encim za bolezen lizosomskega shranjevanja
WO2012012461A2 (en) 2010-07-19 2012-01-26 Shire Human Genetic Therapies, Inc. Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof
KR20150038636A (ko) 2010-09-09 2015-04-08 시나게바 바이오파르마, 코포레이션 환자에서 리소좀 산 리파제 결핍증의 치료를 위한 리소좀 산 리파제의 용도
EP2675472A4 (en) 2011-02-15 2014-09-17 Synageva Biopharma Corp METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
PL3257564T5 (pl) * 2011-11-02 2024-10-07 F. Hoffmann-La Roche Ag Chromatografia elucyjna z przeładowaniem
EP2863941B1 (en) 2012-03-02 2018-12-19 Shire Human Genetic Therapies, Inc. Velaglucerase for treating type iii gaucher disease
EP2866839B1 (en) * 2012-06-29 2018-08-15 Consejo Superior De Investigaciones Científicas (CSIC) Functionalized liposomes useful for the delivery of bioactive compounds
JP6226435B2 (ja) * 2012-07-26 2017-11-08 Ｊｃｒファーマ株式会社 組換えヒトα−ガラクトシダーゼＡの製造方法
WO2014016873A1 (en) * 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
DK2911759T3 (da) 2012-10-24 2024-09-16 Genzyme Corp Eluering af biomolekyler fra multimodale harpikser under anvendelse af mes og mops som modifikatorer af den mobile fase
TWI793159B (zh) 2013-10-23 2023-02-21 美商健臻公司 重組醣蛋白及其用途
PL3237621T3 (pl) * 2014-12-22 2023-10-30 Codexis, Inc. Warianty ludzkiej alfa-galaktozydazy
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
JP6903295B2 (ja) 2017-06-30 2021-07-14 富士フイルム株式会社 ライソゾーム病処置剤
ES2716305B2 (es) 2017-12-11 2019-11-27 Fund Biomedica Galicia Sur Uso de chaperonas farmacologicas para el tratamiento de enfermedades de deposito lisosomal
JP2022515742A (ja) 2018-12-20 2022-02-22 コデクシス， インコーポレイテッド α－ガラクトシダーゼバリアント
CN111308095A (zh) * 2020-03-04 2020-06-19 北京师范大学 用于诊断前列腺癌的尿液蛋白标记物
TW202423959A (zh) * 2022-08-24 2024-06-16 美商步行魚醫療公司 用於治療法布瑞氏症(fabry disease)之組成物及方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2619719B1 (fr) * 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
ES2061585T3 (es) * 1987-10-02 1994-12-16 Zymogenetics Inc Señal de secrecion de bar1.
EP0463109A4 (en) * 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
IL95330A0 (en) * 1989-08-11 1991-06-30 Lilly Co Eli Expression of a functional insect specific toxin gene in mammalian cells
JPH06502071A (ja) * 1990-09-28 1994-03-10 ジ・アップジョン・カンパニー アルツハイマーのアミロイド前駆遺伝子を有するトランスジェニック動物
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
JPH06503479A (ja) * 1991-10-16 1994-04-21 オラージェン，　インコーポレイテッド 動物体細胞の粒子−媒介トランスフォーメーション
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
SE9300105D0 (sv) * 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
CA2166488A1 (en) * 1993-07-02 1995-01-12 Marian N. Marra Glycosylated and non-glycosylated bactericidal/permeability increasing proteins, and methods for producing same
ATE320482T1 (de) 1994-01-13 2006-04-15 Rogosin Inst Makroeingekapselte sekretorische zellen
JP2984552B2 (ja) * 1994-09-02 1999-11-29 大和化成株式会社 ラッカーゼおよびその生産方法
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
JPH08196293A (ja) * 1995-01-25 1996-08-06 Mitsui Toatsu Chem Inc タンパク質の製造方法
AU691410B2 (en) * 1995-02-15 1998-05-14 Amgen, Inc. MPL ligand analogs

Also Published As

Publication number Publication date
PL190041B1 (pl) 2005-10-31
JP2012019793A (ja) 2012-02-02
DE69732129T2 (de) 2005-12-08
HUP9904666A3 (en) 2001-09-28
IL128960A0 (en) 2000-02-17
HU227189B1 (en) 2010-10-28
CA2265464C (en) 2007-06-26
TW585919B (en) 2004-05-01
JP4313405B2 (ja) 2009-08-12
NO20090583L (no) 1999-05-10
ES2458292T3 (es) 2014-04-30
DK1538202T3 (en) 2014-03-24
HU230275B1 (hu) 2015-11-30
KR20000036078A (ko) 2000-06-26
AU4424497A (en) 1998-04-02
IL184637A (en) 2015-07-30
NZ506214A (en) 2002-11-26
EP1538202A2 (en) 2005-06-08
EP1538202A3 (en) 2007-05-30
IL184637A0 (en) 2009-09-22
NO340408B1 (no) 2017-04-18
EP0935651A2 (en) 1999-08-18
RU2179034C2 (ru) 2002-02-10
HK1022173A1 (en) 2000-07-28
ES2234032T3 (es) 2005-06-16
EP2374876A2 (en) 2011-10-12
NO991225L (no) 1999-05-10
JP2001504324A (ja) 2001-04-03
KR100547402B1 (ko) 2006-02-01
HK1162580A1 (zh) 2012-08-31
DK2374876T3 (en) 2016-05-30
HK1074058A1 (en) 2005-10-28
EP0935651B1 (en) 2004-12-29
NO328443B1 (no) 2010-02-22
CA2265464A1 (en) 1998-03-19
MX340738B (es) 2016-07-22
ATE286120T1 (de) 2005-01-15
JP2009102321A (ja) 2009-05-14
EP2327775A2 (en) 2011-06-01
WO1998011206A3 (en) 1998-08-13
EP2374876B1 (en) 2016-04-13
ES2581828T3 (es) 2016-09-07
JP2007289201A (ja) 2007-11-08
JP2009060918A (ja) 2009-03-26
KR20050084473A (ko) 2005-08-26
PL332188A1 (en) 1999-08-30
JP4001925B2 (ja) 2007-10-31
JP5590788B2 (ja) 2014-09-17
HU1000445D0 (en) 2010-11-29
EP2374876A3 (en) 2012-10-24
IL128960A (en) 2007-10-31
NO330687B1 (no) 2011-06-06
CN1268741C (zh) 2006-08-09
NZ334721A (en) 2001-01-26
DE69732129D1 (de) 2005-02-03
JP4313381B2 (ja) 2009-08-12
EP1538202B1 (en) 2014-01-22
NO20141168L (no) 1999-05-10
WO1998011206A2 (en) 1998-03-19
JP2015044830A (ja) 2015-03-12
EP2327775A3 (en) 2012-10-24
NO20110496L (no) 1999-05-10
JP2007000145A (ja) 2007-01-11
HU9904666A (en) 2000-05-28
CN1230220A (zh) 1999-09-29
PT1538202E (pt) 2014-04-22

Similar Documents

Publication Publication Date Title
NO991225D0 (no) Terapi for &lt;alfa&gt;-galaktosidase A mangel
AU643673B2 (en) Catalysts for the polymerization of olefins
ID30373A (id) PARAHERKUAMIDA ANTIPARASIT (Pecahan P-962086)
AU5534996A (en) Antibody purification by low-pH hydrophobic interaction chromatography
DE19781288T1 (de) Opake Reaktionsmatrix zur Analyse von Vollblut
DK0832097T3 (da) System og fremgangsmåde til modifikation og rensning af peptider
DE69612991D1 (de) System zur bearbeitung von selbstmodifizierendem kode
PT1027339E (pt) Metodo e reagentes para a n-alquilacao de ureidos
DE69832901D1 (de) Reglungsprozess für die desinfizierung von flüssigkeiten
ES2125938T3 (es) Procedimiento para la reactivacion de proteinas membranales purificadas.
FR2674248B1 (fr) Procede de modification chimique des proteines.
WO1997035015A3 (de) Tyrosin-phosphatase-verwandtes protein
EP0429060A3 (en) Benzothiazepines
TW234126B (no)
WO1997005253A3 (de) Transketolase-verwandtes protein
FR2702777B1 (fr) Procede de nickelage chimique.
ITTO930166A0 (it) Procedimento per il trattamento di flussi reflui della produzione di n-fosfonometilglicina.
HUT67823A (en) Process for the production of leather treating substance from environment-damaging, protein sewage
ES1026348Y (es) Grapilla/abrazadera, para montaje de componentes de lamparas o analogos.
RU2069492C1 (ru) Штамм бактерий rhodococcus species 1418 (r.ruber), используемый для очистки почв и водоемов от нефти и нефтепродуктов
FI963244A (fi) Menetelmä 2-butyyli-2-etyyli-1,3-propaanidiolin erottamiseksi sitä sisältävistä reaktioseoksista
DK0813518T3 (da) Fremgangsmåde til fremstilling af alfa,beta-diaminoacrylnitriler
PL308056A1 (en) Compound reactor for biological sewage treatment

Legal Events

Date Code Title Description
MK1K Patent expired